Cetera Advisors LLC Acquires 3,682 Shares of Johnson & Johnson (NYSE:JNJ)

Cetera Advisors LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.5% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 149,625 shares of the company’s stock after purchasing an additional 3,682 shares during the period. Cetera Advisors LLC’s holdings in Johnson & Johnson were worth $24,766,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Atlantic Private Wealth LLC bought a new stake in shares of Johnson & Johnson during the 1st quarter worth $32,000. 25 LLC bought a new position in Johnson & Johnson in the first quarter valued at about $55,000. Horizons Wealth Management raised its position in Johnson & Johnson by 1,730.0% in the second quarter. Horizons Wealth Management now owns 366 shares of the company’s stock valued at $61,000 after purchasing an additional 346 shares during the last quarter. Bay Harbor Wealth Management LLC bought a new position in Johnson & Johnson in the second quarter valued at about $66,000. Finally, Mcmillion Capital Management Inc. bought a new position in Johnson & Johnson in the second quarter valued at about $103,000. 68.40% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on JNJ shares. HSBC started coverage on Johnson & Johnson in a research report on Wednesday, September 6th. They issued a “hold” rating and a $175.00 target price for the company. Royal Bank of Canada started coverage on Johnson & Johnson in a research report on Wednesday, October 4th. They set an “outperform” rating and a $178.00 price objective for the company. Wells Fargo & Company lowered their price objective on Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating for the company in a research report on Thursday, August 31st. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 26th. Finally, Barclays raised their price objective on Johnson & Johnson from $158.00 to $162.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 12th. Eight analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $169.19.

Johnson & Johnson Trading Up 0.9 %

Shares of Johnson & Johnson stock opened at $149.91 on Tuesday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.96 and a current ratio of 1.21. Johnson & Johnson has a 52 week low of $144.95 and a 52 week high of $181.04. The stock has a 50 day moving average price of $154.52 and a two-hundred day moving average price of $160.29. The stock has a market capitalization of $360.88 billion, a PE ratio of 11.13, a price-to-earnings-growth ratio of 3.00 and a beta of 0.58.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 17th. The company reported $2.66 EPS for the quarter, beating analysts’ consensus estimates of $2.52 by $0.14. Johnson & Johnson had a return on equity of 37.14% and a net margin of 36.32%. The firm had revenue of $21.35 billion during the quarter, compared to analysts’ expectations of $21 billion. As a group, equities analysts anticipate that Johnson & Johnson will post 10.1 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 5th. Investors of record on Tuesday, November 21st will be given a dividend of $1.19 per share. The ex-dividend date is Monday, November 20th. This represents a $4.76 annualized dividend and a dividend yield of 3.18%. Johnson & Johnson’s payout ratio is 35.34%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.